CD8A and cancer: PD‐1 in platelets then binds to PD‐L1 on cancer to reverse cytotoxic T lymphocyte (CD8+ T cell) activity, reducing postoperative tumor recurrence and metastasis.[26] DCs are “professional” antigen‐presenting cells (APCs) capable of processing and presenting antigens to initiate T‐cell‐mediated immune responses.[27] Furthermore, major histocompatibility complex (MHC) class I (MHC‐I) molecules on the surface of DCs play a critical role in inducing specific cytotoxic T cell activation.[28] With the above in mind, Liu et al.